CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Novelion Therapeutics Inc (USA) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Novelion Therapeutics Inc (USA)
400 Burrard Street
Suite 1680
Phone: (604) 707-7000p:604 707-7000 Vancouver, BC  V6C 3A6  Canada Fax: (604) 707-7000f:604 707-7000
Filed for Protection from its Creditors under the Companies' Creditors Arrangement Act (Canada) on 11/5/2019
On 11/5/2019, the Company's Shareholders approved the Voluntary Liquidation and Dissolution of the Company pursuant to the Business Corporations Act (British Columbia)(the "BCBCA"). Alvarez & Marsal Canada Inc. was appointed as the Liquidator of the Company pursuant to Section 319(2)(a) of the BCBCA.
On 11/18/2019, Novelion Therapeutics Inc. filed a petition with the Supreme Court of British Columbia seeking orders affirming the appointment of the Liquidator, granting a stay of proceedings against the Company, and approving a Court-supervised process to solicit and determine any claims against the Company.
On 1/16/2020, Novelion Therapeutics Inc. announced the implementation of its voluntary liquidation (the “Liquidation”) as of 5:00 p.m. Pacific Time.
This company is no longer actively traded on any major stock exchange.
Business Summary
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201912/31/2018YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer, Senior Vice President Michael D.Price 62 12/31/2019 12/4/2017
Director Jason M.Aryeh 50 7/3/2018 6/4/2012
Director AnneVanlent 11/29/2016 11/29/2016

Business Names
Business Name
Aegerion İlaç Ticaret Limited Şirketi
Aegerion Argentina S.R.L.
Aegerion Brasil Comercio E Importacao De Medicamentos LTDA
24 additional Business Names available in full report.

General Information
Number of Employees: 109 (As of 12/31/2018)
Outstanding Shares: 19,618,946 (As of 9/13/2019)
Shareholders: 79
Stock Exchange: OTC
Federal Tax Id: 000007802
Fax Number: (604) 707-7000
Email Address: ir@qltinc.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023